^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Libtayo (cemiplimab-rwlc) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PD-L1 ≥50% First-Line Therapy....The following regimens added as Other Recommended…Cemiplimab-rwlc + pemetrexed + (carboplatin or cisplatin) (nonsquamous) (category 1).
    Secondary therapy:
    carboplatin + pemetrexed; cisplatin + pemetrexed
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    Libtayo® (cemiplimab) approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer expressing PD-L1 in >= 50% of tumour cells with no EGFR, ALK or ROS1 aberrations

    Excerpt:
    Libtayo® (cemiplimab) is now approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test with no EGFR, ALK, or ROS1 aberrations...